# OnCo record nct05296564 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05296564/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05296564", "NCT05296564" ;
  schema:name "Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers"@en ;
  schema:description "A phase 1/2 trial of cyclophosphamide and aldesleukin (high-dose il-2) in triple-negative breast cancer, run by Hadassah Medical Organization, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05296564/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05296564> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "tnbc-deep-dive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/aldesleukin/> .